SWTX (SpringWorks Therapeutics) EBITDA Margin % : -115.74% (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is SpringWorks Therapeutics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. SpringWorks Therapeutics's EBITDA for the three months ended in Sep. 2024 was $-57.1 Mil. SpringWorks Therapeutics's Revenue for the three months ended in Sep. 2024 was $49.3 Mil. Therefore, SpringWorks Therapeutics's EBITDA margin for the quarter that ended in Sep. 2024 was -115.74%.

SpringWorks Therapeutics EBITDA Margin % Historical Data

The historical data trend for SpringWorks Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SpringWorks Therapeutics EBITDA Margin % Chart

SpringWorks Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBITDA Margin %

Get a 7-Day Free Trial

-131.36

-6,266.68

SpringWorks Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBITDA Margin %	Get a 7-Day Free Trial															-	-1,797.78	-443.69	-73.79	-115.74

Competitive Comparison of SpringWorks Therapeutics's EBITDA Margin %

For the Biotechnology subindustry, SpringWorks Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SpringWorks Therapeutics's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SpringWorks Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where SpringWorks Therapeutics's EBITDA Margin % falls into.

SpringWorks Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

SpringWorks Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-341.346	/	5.447
	=	-6,266.68 %

SpringWorks Therapeutics's EBITDA Margin % for the quarter that ended in Sep. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-57.059	/	49.301
	=	-115.74 %

SpringWorks Therapeutics (NAS:SWTX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

SpringWorks Therapeutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of SpringWorks Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

SpringWorks Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SpringWorks Therapeutics Inc (NAS:SWTX) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Washington Boulevard, Stamford, CT, USA, 06902

Website

https://www.springworkstx.com

SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.

Executives

Badreddin Edris	officer: Chief Business Officer	C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BLVD., STAMFORD CT 06902
Saqib Islam	director, officer: Chief Executive Officer	ALEXION PHARMACEUTICALS, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Julie Hambleton	director	C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Daniel Pichl	officer: Chief People Officer	C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BLVD., STAMFORD CT 06902
Bhavesh Ashar	officer: Chief Commercial Officer	C/O SPRINGWORKS THERAPEUTICS, 100 WASHINGTON BLVD, STAMFORD CT 05902
Tai-an Lin	officer: Chief Scientific Officer	C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BOULEVARD, STAMFORD CT 06902
Jeffrey Lawrence Schwartz	director, 10 percent owner	C/O BAIN CAPITAL LIFE SCIENCES, LP, 200 CLARENDON STRERET, BOSTON MA 02116
James Cassidy	officer: Chief Medical Officer	368 NOD HILL ROAD, WILTON CT 06897
Orbimed Advisors Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carlos Alban	director	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
L. Mary Smith	officer: See Remarks	C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BLVD., STAMFORD CT 06902
Bain Capital Life Sciences Investors, Llc	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Michael F. Burgess	officer: Head of Research & Development	C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMRIDGE MA 02142
Stephen P Squinto	director, 10 percent owner	C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Orbimed Capital Gp Vi Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022